Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ASBRON vs ACCURBRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.
Relief of symptoms of acute bronchial asthma and reversible bronchospasm associated with chronic bronchitis and emphysema,Symptomatic relief of productive cough associated with respiratory conditions
FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.
Theophylline is primarily metabolized by cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Guaifenesin is metabolized via oxidation and glucuronidation.
Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
50-60% bound to albumin and alpha-1-acid glycoprotein
85-90% bound to albumin.
0.3-0.5 L/kg; indicates distribution primarily into extracellular fluid
0.8-1.2 L/kg (wide distribution into tissues, including lungs).
Oral: 40-60%; rectal: 50-70%; inhalation: 10-30%
Oral: 60-80% (first-pass metabolism reduces bioavailability).
GFR 30-59 m L/min: reduce dose by 25-50%; GFR <30 m L/min: reduce dose by 50% and monitor serum theophylline levels.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B or C: reduce dose by 75% and monitor serum theophylline levels.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.
Weight-based: 10-16 mg/kg/day theophylline equivalent divided every 6-8 hours; maximum 400 mg/day. Adjust based on serum levels.
Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.
Elderly patients: initial dose of 130 mg orally every 8 hours; titrate gradually; monitor serum theophylline levels due to reduced clearance.
No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).
Theophylline has a narrow therapeutic index; serious adverse effects including seizures and arrhythmias can occur at levels close to therapeutic range. Do not exceed recommended doses. Use caution in patients with cardiac or hepatic impairment.
No FDA boxed warning exists for this combination product.
Theophylline toxicity is dose-related; monitor serum levels. Caution in patients with peptic ulcer, hyperthyroidism, seizure disorders, or cardiovascular disease. Drug interactions with quinolones, macrolides, and cimetidine can increase theophylline levels.
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.
Hypersensitivity to theophylline or guaifenesin, active peptic ulcer disease, seizure disorders (unless controlled), and severe cardiac arrhythmias.
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
Avoid high-fat meals with extended-release formulations as they may alter absorption. Limit caffeine-containing foods/beverages (coffee, tea, chocolate) due to additive CNS stimulation. No significant food interactions with guaifenesin.
High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.
Asbron contains theophylline and guaifenesin. Theophylline: In first trimester, limited data suggest no major teratogenic risk (FDA category C). In second and third trimesters, no known teratogenicity but may cause fetal tachycardia, jitteriness, or transient neonatal effects (e.g., irritability, vomiting) due to transplacental passage. Guaifenesin: Limited human data; animal studies not indicative of teratogenicity. Overall, Asbron is considered relatively low risk, but non-pharmacologic measures preferred in first trimester.
No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.
Theophylline is excreted into breast milk with an average milk-to-plasma ratio of 0.67. Maximum milk concentration correlates with maternal serum levels. With typical maternal doses, infant serum levels may reach 2-4 mcg/m L, rarely causing irritability or poor feeding. Guaifenesin is likely minimally transferred. Asbron is considered compatible with breastfeeding; observe infant for signs of theophylline side effects (jitteriness, insomnia).
Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.
Theophylline clearance increases by 20-30% in pregnancy due to increased hepatic metabolism and volume of distribution, particularly in second and third trimesters. Starting doses should be based on non-pregnant recommendations, but maintenance doses may need to be increased by up to 30% to achieve therapeutic levels. Monitor serum levels every 1-2 weeks and adjust dose to maintain trough 5-10 mcg/m L (lower end to minimize fetal exposure). Postpartum, clearance decreases rapidly; reduce dose and monitor levels closely to avoid toxicity.
No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline has a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L) due to variable metabolism. Guaifenesin is an expectorant but evidence for efficacy is limited. Avoid in patients with active peptic ulcer disease or seizure disorders. Cimetidine, fluoroquinolones, and macrolides increase theophylline levels; smoking and rifampin decrease levels.
Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.
Take Asbron exactly as prescribed; do not crush or chew extended-release tablets.,Avoid excessive caffeine intake (coffee, tea, cola) as it may increase side effects.,Report symptoms of theophylline toxicity: nausea, vomiting, insomnia, tremors, fast heartbeat.,Do not stop abruptly; dosage tapering may be needed.,Stay hydrated to help guaifenesin work effectively.,Avoid alcohol as it may increase side effects like dizziness.
Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ASBRON vs ACCURBRON, answered by our medical review team.
ASBRON is a Bronchodilator that works by Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ASBRON and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ASBRON is: 1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ASBRON and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ASBRON is classified as Category C. Asbron contains theophylline and guaifenesin. Theophylline: In first trimester, limited data suggest no major teratogenic risk (FDA category C). In second and third trimesters, no . ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.